Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P012 - Pooled Safety Analysis for Two Generations ALK Inhibitors: A Meta Analysis (ID 31)
00:00 - 00:00 | Author(s): D. Sun
2% - 7% NSCLC patients were detected to have ALK mutation. At present, two or more generations ALK inhibitors have been used for ALK positive NSCLC treatment which including crizotinib, alectinib, ceritinib, brigatinib and so on. Although, most of the adverse events(AEs) of ALK inhibitors are grade 1 to grade 2 and can be generally well tolerated, the serious adverse events(SAEs) of ALK inhibitors are lack of huge data analysis as we know and the lung toxicity of ALK inhibitors is needed to be payed attention to. Thus, we performed meta analysis to evaluate the safety of ALK inhibitors and especially the SAEs.
16 studies from 4 database (Pubmad, Science Direct, ClinicalTrials.gov and Cochrane Library) were included in this meta analysis. All statistical analyses in this meta analysis were performed by STATA 14.0 software. We analyzed the incidence of pooled AEs, the incidence of pooled SAEs and the incidences of common types of SAEs of ALK inhibitors.
The pooled AEs of ALK inhibitors almost occurred in all participates and the pooled SAEs occurred in over 20% participates. Especially ceritinib and brigatinib, of which the SAEs occurred in over 40% participates. It is likely that alectinib is safest ALK inhibitors of the two generations ALK inhibitors. Generally, ALK inhibitors shows significant lung toxicity.
In conclusion, the ALK related SAEs should draw our attention especially the lung toxicity. According to this meta analysis, alectinib seems to be the safest ALK inhibitor. Physicians should focus on the related SAEs when using ALK inhibitors.